CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About CADTH What We Do Programs and Services CADTH Common Drug Review Reports Pegaptanib sodium

Pegaptanib sodium

Last Updated: October 20, 2005

Result type: Reports

Project Number: S0044

Product Line: Common Drug Review

Generic Name: Pegaptanib sodium

Brand Name: Macugen

Manufacturer: Pfizer Canada Inc.

Indications: Macular degeneration, age-related

Submission Type: New

Project Status: Complete

Date Recommendation Issued: May 25, 2006

Recommendation Type: Do not list

Pegaptanib sodium

Files